A Phase III Study of Nimotuzumab Plus Concurrent Chemoradiotherapy in Loco-regional Esophageal Squamous Cell Carcinoma

NCT02409186 · clinicaltrials.gov ↗

PHASE3

Phase

UNKNOWN

Status

200

Enrollment

OTHER

Sponsor class

Conditions

Prosthesis Survival

Interventions

DRUG: Nimotuzumab
RADIATION: radiotherapy
DRUG: chemoradiotherapy Paclitaxel
DRUG: chemoradiotherapy Cisplatin
OTHER: placebo

Sponsor

Shandong Cancer Hospital and Institute